CWM
VRTX icon

Cabot Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cabot Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$415K Hold
930
– – 0.05% 106
2025
Q4 		$422K Sell
930
-645
-41% -$278K 0.05% 108
2025
Q3 		$617K Buy
+1,575
New +$658K 0.07% 105

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cabot Wealth Management's VRTX Position: Q1 2026 in Review

Cabot Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 930 shares worth $415K. The position accounts for 0.05% of the portfolio, ranked #106.

Cabot Wealth Management first reported a position in VRTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $617K in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Cabot Wealth Management held 930 shares of Vertex Pharmaceuticals worth $415K as of Q1 2026.
  • Cabot Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.05% of Cabot Wealth Management's portfolio in Q1 2026, its #106 holding.
  • Cabot Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Cabot Wealth Management's Vertex Pharmaceuticals position peaked at $617K in Q3 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cabot Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.